IP Library Granted Patent US 8,357,708
Granted Patent B2
US 8,357,708 · App. 13/331,497 · Granted Jan 22, 2013

Macrocyclic compounds and methods of treatment

Inventors: Hendrik Luesch (Gainesville, FL); Taori Kanchan (Gainesville, FL); Valerie J. Paul (Fort Pierce, FL)
Assignees: University of Florida Resesarch Foundation, Inc.; Smithsonian Institutution
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,357,708
App. No.
13/331,497
Granted
Jan 22, 2013
Kind
B2
Abstract

The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.

Claims (39)

1. A kit comprising an effective amount of a compound of formula (I), in unit dosage form, together with instructions for administering the compound to a subject suffering from a cell proliferation disorder that is breast cancer, osteosarcoma, colon cancer, or neuroblastoma:

wherein:

each R is independently H or optionally substituted alkyl;

each R 1 is independently H, or optionally substituted alkyl;

each R 2 is independently H, optionally substituted alkyl, or C(O)R;

each R 3 is independently H, optionally substituted alkyl, C(O)OR, or C(O)NRR;

each R 4 is independently H, optionally substituted alkyl, C(O)OR, or C(O)NRR;

and pharmaceutically acceptable salts, solvate, or hydrate thereof.

2. A method of modulating the activity of cell proliferation in a subject, comprising contacting the subject with a compound of formula I, in an amount and under conditions sufficient to modulate cell proliferation, wherein the cell is selected from breast cancer, osteosarcoma, colon cancer, or neuroblastoma cells:

wherein:

each R is independently H or optionally substituted alkyl;

each R 1 is independently H, or optionally substituted alkyl;

each R 2 is independently H, optionally substituted alkyl, or C(O)R;

each R 3 is independently H, optionally substituted alkyl, C(O)OR, or C(O)NRR;

each R 4 is independently H, optionally substituted alkyl, C(O)OR, or C(O)NRR;

and pharmaceutically acceptable salts, solvate, or hydrate thereof.

3. The method of claim 2 , wherein the cell is a tumor cell.

4. The method of claim 2 , wherein the modulation is inhibition.

5. A method of therapeutically treating a subject suffering from a cell proliferation related disorder or disease that is breast cancer, osteosarcoma, colon cancer, or neuroblastoma, wherein the subject has been identified as in need of treatment for a cell proliferation related disorder or disease, comprising administering to said subject in need thereof, an effective amount of a compound or pharmaceutical composition of formula I, such that said subject is treated for said disorder:

wherein:

each R is independently H or optionally substituted alkyl;

each R 1 is independently H, or optionally substituted alkyl;

each R 2 is independently H, optionally substituted alkyl, or C(O)R;

each R 3 is independently H, optionally substituted alkyl, C(O)OR, or C(O)NRR;

each R 4 is independently H, optionally substituted alkyl, C(O)OR, or C(O)NRR;

and pharmaceutically acceptable salts, solvate, or hydrate thereof.

6. The method of claim 2 or 5 , wherein the compound of formula I is one of Compounds 1-8:

7. The method of claim 5 , wherein the disorder is an angiogenesis disorder.

8. The method of claim 5 , wherein the disorder is solid tumor.

9. The method of claim 2 or 5 , wherein the subject is a mammal.

10. The method of claim 2 or 5 wherein the subject is a primate or human.

11. The method of claim 2 or 5 , wherein the effective amount of the compound of formula I ranges from about 0.005 μg/kg to about 200 mg/kg.

12. The method of claim 11 , wherein the effective amount of the compound of formula I ranges from about 0.1 mg/kg to about 200 mg/kg.

13. The method of claim 12 , wherein the effective amount of compound of formula I ranges from about 10 mg/kg to 100 mg/kg.

14. The method of claim 2 or 5 , wherein the effective amount of the compound of formula I ranges from about 1.0 pM to about 500 nM.

15. The method of claim 2 or 5 , wherein the compound of formula I is administered intravenously, intramuscularly, subcutaneously, intracerebroventricularly, orally or topically.

16. The method of claim 2 or 5 , wherein the compound of formula I is administered alone or in combination with one or more other therapeutics.

17. The method of claim 16 , wherein the additional therapeutic agent is an anti-cancer agent, chemotherapeutic agent, an anti-angiogenesis agent, cytotoxic agent, or an anti-proliferation agent.

18. A method of therapeutically treating a cancer or tumor that is breast cancer, osteosarcoma, colon cancer, or neuroblastoma, comprising administering to said subject in need thereof, an effective amount of any of Compounds 1-8, and pharmaceutically acceptable salts thereof:

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2012
From: LUESCH, HENDRICK; KANCHAN, TAORI; PAUL, VALERIE J.
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 028036/0802 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2012
From: PAUL, VALERIE
To: SMITHSONIAN INSTITUTION
Reel/Frame 027614/0443 →
Continuity (7)
Division 12677078
Provisional Application 60970986 · Sep 9, 2007
Provisional Application 61009903 · Jan 3, 2008
Provisional Application 61030993 · Feb 24, 2008
Provisional Application 61125542 · Apr 24, 2008
Provisional Application 61189093 · Aug 15, 2008
Related Publication 20120095065A1 · Apr 19, 2012